Now Live: Cboe Europe real-time data for all major European stocks.
United States
opens in 4h 52m
Pre-market

STOCKS is currently open for pre-market.
Main market opens in 4 hours 52 minutes

04:37
00:00
09:30
16:00
23:59

Trading Hours (Monday - Friday):

Pre-market
04:00 - 09:30
Main market
09:30 - 16:00
Post-market
16:00 - 20:00
All times are displayed in the America/New_York timezone (EST, UTC-05:00).
CSL Limited logo
202.52 AUD
0.4
0.20%
Last update Nov 16, 3:59 PM AEDT
Market closed
Day range
199.75999
202.52
Previous close
202.92000
Open
200.81000
Access this stock data via API
Subscribe
CSL Limited logo
CSL Limited
202.52
0.40
0.20%

Overview

Access /time_series data via our API — starting from the Basic plan and above.

Description

CSL Limited is a leading Australian multinational biotechnology company specializing in the research, development, manufacturing, and marketing of lifesaving medicines and vaccines. The company’s portfolio includes plasma-derived therapies for conditions such as hemophilia and immune deficiencies, influenza vaccines, and treatments for rare and serious diseases. CSL operates globally through its core divisions—CSL Behring, CSL Seqirus, and CSL Vifor—serving patients in over 100 countries. With a history dating back to 1916, CSL has played a pivotal role in advancing public health, including during major global health events like the COVID-19 pandemic. The company is listed on the CHI-X Market Australia – Limit Venue, providing investors access to one of the largest and most innovative biotech firms in the Asia-Pacific region. CSL’s commitment to scientific innovation and global health continues to shape the biotechnology sector and drive advancements in patient care.

About

CEO
Mr. Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.
Employees
29000
Address
655 Elizabeth Street
Melbourne, 3000, VIC
Australia
Phone
61 3 9389 1911
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Australia
MIC code
XASX
Access /profile data via our API — starting from the Grow plan (individual) and the Venture plan (business) and above.

Latest press releases

Oct 21, 2026
CSL appoints Deborah Waterhouse as CEO & Managing Director

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors. 

Ms Waterhouse is a proven commercial leader with more than 25 years' experience managing complex global specialty pharma companies across the U.S., the U.K., continental Europe and Australia.  

Since 2017 Ms Waterhouse has been the CEO of ViiV Healthcare, a joint venture majority owned by GSK with Shionogi as a shareholder. ViiV is a leading specialist in HIV and had sales of £7.7 billion during GSK's 2025 financial year[i]. Additionally, Ms Waterhouse serves as the President of GSK Global Health.

Ms Waterhouse has previously led GSK's U.S. vaccines business and its U.S. Primary Care business and has held several other senior executive positions, including GSK's General Manager for Australia and New Zealand between 2008 and 2012.

CSL Chair Dr Brian McNamee said, "In February this year we said CSL's next chief executive would need the ability to continue the momentum of our commercial performance, renew our pipeline and simplify our operations without losing the science and purpose that built this great company. Deborah has done all those things on multiple occasions. Deborah is an outstanding global leader with a proven ability to grow complex businesses."

"She has grown a focused biopharmaceutical business and renewed the franchise at ViiV by driving the development and commercialisation of the next generation of medicines to support patients. She knows the United States, she knows Australia and she knows how to build pipelines and manage partnerships. A world-class and purpose-driven executive, she is the right person to lead CSL in its next chapter of growth. The Board's decision to appoint Deborah was unanimous."

Ms Waterhouse said, "CSL is one of the great companies in our industry, and I saw what it means to Australia when I lived and worked in Melbourne. Its people save lives every day, from the staff who collect plasma at the donation centres to the scientists and operators who develop and manufacture the medicines and vaccines. The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders."

Ms Waterhouse will retain her base in the U.K. She will spend significant time in Australia, the U.S. and in CSL's major markets and operational centres. Gordon Naylor will continue as Interim CEO and Managing Director until 1 February 2027. He will conduct an appropriate transition with Ms Waterhouse and will resume his role on the Board as a non-Executive Director. 

A biography for Ms Waterhouse is set out in Attachment 1.

The key components of Ms Waterhouse's employment contract, including her remuneration structure, effective from 1 February 2027 are set out in Attachment 2.

Authorised for lodgement by:

Fiona Mead

Company Secretary

 

Investor Relations

 

Media Relations



Michelle Rees

P: +61 410 600 745

E: michelle.rees@csl.com.au 

Brett Foley

P: +61 461 464 708

E: brett.foley@csl.com.au 



CSL Limited | ABN 99 051 588 348 | 655 Elizabeth Street, Melbourne VIC 3000

Attachment 1: 

Career Summary for Ms Waterhouse

GSK Career Summary



Period

Title

2017 – Present day

CEO ViiV Healthcare and President GSK Global Health

2015 – 2017

SVP US Primary Care Business Unit 

2013 – 2015                                                           

SVP US Vaccines Business Unit

2012 – 2013

SVP Central and Eastern Europe

2008 – 2012

VP General Manager Australia and New Zealand

2008

VP Human Resources Europe          

2004 – 2007

Business Unit Head HIV UK and Head of HIV Europe

1999 – 2004

Global Commercialisation Leader

1996 – 1999

Sales and Marketing roles of increasing seniority in GSK UK





Board of Director Appointments

Period

Title

2017 – Present Day          

Member of the ViiV Healthcare Board of Directors

2019 – 2025  

Non-Executive Director Schroders: Member of Board of Directors, Audit

and Risk, Remuneration and Nominations Committees

July 2026 – Present Day

Non-Executive Director, Reckitt







Attachment 2:

Key Employment Terms for Ms Waterhouse


Key Term

Details

Commencement

date
 

1 February 2027.

Base salary 

£1,500,000 per annum.

STI 

First award is FY27 STI:  

  • 120% of Base Salary at Target and 240% of Base Salary at Maximum (pro-

    rated from Commencement Date).
  • 30% to be deferred for 2 years as equity award.

    Entitled to participate in future STI grants on terms approved by the Board. 

LTI 

First award is September 2027 LTI: 

  • 250% of Base Salary at Target and 500% of Base Salary at Maximum.
  • Performance period 1 July 2027 to 30 June 2030 (scheduled to vest 1

    September 2030).

    Entitled to participate in future LTI grants on terms approved by the Board. 

    Shareholder approval will be sought for these grants consistent with CSL's

    usual approach. 

Buyout of GSK

awards
 to be

forfeited

  • Award of Restricted Stock Units (RSUs) with a value of £7.71m (subject to

    adjustment prior to grant, based on the next GSK vesting outcome). The

    award is scheduled to vest on 1 March 2028, subject to service conditions.  

Extra award to

address LTI

timing
 

  • Award of £1.65m Performance Stock Units (PSUs) that vest on 1 September

    2029, subject to the same TSR vesting conditions attached to CSL's

    1 September 2026 LTI award and service conditions (including 12-month

    holding lock post-vesting). 
  • Designed to recognise the extended gap that her move will create

    between annual awards received at GSK and the first annual CSL award

    that she is scheduled to receive in October 2027. 

Pension 

  • Arrangements aligned with UK workforce.  Due to tax rules, it is

    anticipated that the CEO will receive a cash allowance equivalent to 10% of

    base salary less the prevailing rate of employers' national insurance

    contribution in lieu of employer pension contributions. 

Benefits 

  • Standard UK benefits – including private medical insurance, 6 x salary life

    assurance and income protection insurance. 

Notice period 

  • 12 months' notice by CEO or CSL.   
  • Customary garden leave, summary termination and payment in lieu of

    notice provisions. 

Restrictive

covenant (while 

at
 CSL) 

  • Restricted from being involved in the CSL Seqirus business until 31 March

    2027, due to previous employment in a competitive business. 

Restrictive

covenants (after

CSL) 

  • 6 month post-termination non-compete. 
  • 12 month post-termination non-solicit / non-deal with customers, non-

    interfere with suppliers and non-solicit of key employee. 
  • Duration of restrictions reduced by any period spent on garden leave. 

Tax

arrangements
 

  • CEO to be responsible for UK taxes.  
  • CSL to be responsible for taxes outside of the UK. 

Other 

  • CSL Minimum Security Holding Policy applies – 300% of Base Salary for

    CEO. 

[i] According to GSK's FY25 accounts

Cision View original content:https://www.prnewswire.co.uk/news-releases/csl-appoints-deborah-waterhouse-as-ceo--managing-director-302915181.html

Oct 4, 2026
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared

MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.

Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and anti-fibrotic effects to potentially prevent and reverse organ damage in ANCA-associated vasculitis (AAV) and numerous other kidney, liver and lung diseases. The ongoing phase 2 trial is designed to translate these mechanistic effects into meaningful clinical impact.  

The collaboration brings together Alentis' scientific expertise as the leading clinical-stage biopharmaceutical company targeting claudin-1 and CSL's global development and commercialisation capabilities in nephrology, with a shared goal of bringing innovative and highly impactful treatment options to patients with rare kidney and liver diseases. In addition to AAV-RPGN, the two companies will advance lixudebart as a novel treatment for focal segmental glomerulosclerosis (FSGS), a rare progressive kidney disease, and for primary sclerosing cholangitis (PSC), an autoimmune chronic liver disease.

"This partnership enables us to dramatically accelerate the development of lixudebart in several indications in parallel," said Dr Mark Pruzanski, Chief Executive Officer of Alentis Therapeutics. "We are convinced CSL's demonstrated clinical development and commercialisation capabilities in AAV and kidney diseases makes them the right partner to bring lixudebart to patients. More broadly, this furthers the validation of claudin-1 as a novel therapeutic target and we are excited about the potential to accelerate the advancement of our other clinical stage assets and preclinical pipeline."

"Patients diagnosed with ANCA-associated vasculitis with rapidly progressive glomerulonephritis face rapid kidney function decline, leaving them at risk of irreversible damage even with currently available treatments," said Dr Bill Mezzanotte, EVP, Head of R&D, CSL. "We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease, first in AAV-RPGN and hopefully also in focal segmental glomerulosclerosis, while potentially showing similar benefit on liver function in primary sclerosing cholangitis. Our partnership with Alentis reflects CSL's commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships."

Under the agreement, CSL and Alentis will jointly develop and co-promote lixudebart. CSL will make an initial payment to Alentis of US$355 million, with Alentis eligible to receive up to an additional US$1.2 billion in commercial milestone payments. In addition to these payments, CSL will fully fund the completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial in AAV-RPGN, the Phase 2 trials in FSGS and PSC and other supporting development activities. Once commercialised, global profits will be shared 55 per cent to CSL and 45 per cent to Alentis.

About AAV-RPGN

ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN) is a rare, severe and potentially fatal autoimmune disease in which the body's immune system attacks small blood vessels in the kidney. RPGN is characterized by rapid loss of kidney function over a very short period (days to weeks). Despite potent immunosuppressive treatment, most patients develop significant or total loss of kidney function.

About Lixudebart

Lixudebart (formerly known as ALE.F02) is an investigational monoclonal antibody that selectively targets exposed claudin-1, a key driver of inflammatory and fibrotic signalling pathways in numerous fibrotic diseases of the kidney, liver, lung, intestine and other solid organs. In an interim analysis of 26 patients with AAV-RPGN in the ongoing Phase 2 RENAL trial, lixudebart showed promising improvement in kidney function as assessed by eGFR and proteinuria at 24 weeks. In the Phase 1b FEGATO trial in 41 patients with advanced F3/F4 liver fibrosis, lixudebart demonstrated improved liver function at 6 weeks. In both studies lixudebart showed dose-dependent claudin-1 target engagement, along with a favourable safety and tolerability profile. Lixudebart has been granted Orphan Drug designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs almost 29,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

About Alentis

Alentis is a clinical-stage, privately held biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. Beyond the company's lead antibody for fibrosis, lixudebart, Alentis is developing oncology candidates ALE.P02 and ALE.P03. These are claudin-1 targeted ADCs with a tubulin inhibitor payload and topoisomerase‑I inhibitor payload, respectively. ALE.P02 was granted Fast Track designation by FDA for the treatment of advanced or metastatic claudin-1 expressing squamous cancers, irrespective of the organ of origin. Both ADCs are currently in Phase 1/2 studies enrolling patients with a variety of solid tumor types.

Alentis was founded on the groundbreaking research in the laboratory of Prof. Thomas Baumert, MD, at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). The company is headquartered in Basel, Switzerland. Visit www.alentis.ch

Cision View original content:https://www.prnewswire.co.uk/news-releases/csl-and-alentis-announce-global-partnership-to-develop-and-commercialise-lixudebart-for-rare-kidney-and-liver-diseases-302897834.html

Access /press_releases data via our API — starting from the Basic plan and above.
Market closed

Pre-market opens in 10 hours 22 minutes
Main market opens in 13 hours 22 minutes

20:37
00:00
10:00
16:00
23:59

Trading Hours (Monday - Friday):

Pre-market
07:00 - 10:00
Main market
10:00 - 16:00
Post-market
16:00 - 16:12
All times are displayed in the Australia/Sydney timezone (AEDT, UTC+11:00).